Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model

Haiyan Chu, Subash C. Das, Jeremy F. Fuchs, M. Suresh, Scott Weaver, Dan T. Stinchcomb, Charalambos D. Partidos, Jorge E. Osorio

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Chikungunya virus (CHIKV), a mosquito-borne alphavirus, recently re-emerged in Africa and spread to islands in the Indian Ocean, the Indian subcontinent, and to South East Asia. Viremic travelers have also imported CHIKV to the Western hemisphere highlighting the importance of CHIKV in public health. In addition to the great burden of arthralgic disease, which can persist for months or years, epidemiologic studies have estimated case-fatality rates of ~0.1%, principally from neurologic disease in older patients. There are no licensed vaccines or effective therapies to prevent or treat human CHIKV infections. We have developed a live CHIKV vaccine (CHIKV/IRES) that is highly attenuated yet immunogenic in mouse models, and is incapable of replicating in mosquito cells. In this study we sought to decipher the role of adaptive immunity elicited by CHIKV/IRES in protection against wild-type CHIKV infection. A single dose of vaccine effectively activated T cells with an expansion peak on day 10 post immunization and elicited memory CD4+ and CD8+ T cells that produced IFN-γ, TNF-α and IL-2 upon restimulation with CHIKV/IRES. Adoptive transfer of CHIKV/IRES-immune CD4+ or CD8+ T cells did not confer protection against wtCHIKV-LR challenge. By contrast, passive immunization with anti-CHIKV/IRES immune serum provided protection, and a correlate of a minimum protective neutralizing antibody titer was established. Overall, our findings demonstrate the immunogenic potential of the CHIKV/IRES vaccine and highlight the important role that neutralizing antibodies play in protection against an acute CHIKV infection.

Original languageEnglish (US)
Pages (from-to)3353-3360
Number of pages8
JournalVaccine
Volume31
Issue number33
DOIs
StatePublished - Jul 18 2013

Fingerprint

Chikungunya virus
Adaptive Immunity
Vaccines
animal models
vaccines
Neutralizing Antibodies
Culicidae
T-Lymphocytes
T-lymphocytes
Indian Ocean Islands
neutralizing antibodies
adaptive immunity
Alphavirus
immunization
Passive Immunization
Far East
Adoptive Transfer
infection
Nervous System Diseases
burden of disease

Keywords

  • A129 mice
  • Cellular immunity
  • Chikungunya (CHIKV)
  • Humoral immunity
  • Interferon (IFN)
  • Protection

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. / Chu, Haiyan; Das, Subash C.; Fuchs, Jeremy F.; Suresh, M.; Weaver, Scott; Stinchcomb, Dan T.; Partidos, Charalambos D.; Osorio, Jorge E.

In: Vaccine, Vol. 31, No. 33, 18.07.2013, p. 3353-3360.

Research output: Contribution to journalArticle

Chu, Haiyan ; Das, Subash C. ; Fuchs, Jeremy F. ; Suresh, M. ; Weaver, Scott ; Stinchcomb, Dan T. ; Partidos, Charalambos D. ; Osorio, Jorge E. / Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. In: Vaccine. 2013 ; Vol. 31, No. 33. pp. 3353-3360.
@article{2f998fe63b8541c2acb64fe6fbfde806,
title = "Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model",
abstract = "Chikungunya virus (CHIKV), a mosquito-borne alphavirus, recently re-emerged in Africa and spread to islands in the Indian Ocean, the Indian subcontinent, and to South East Asia. Viremic travelers have also imported CHIKV to the Western hemisphere highlighting the importance of CHIKV in public health. In addition to the great burden of arthralgic disease, which can persist for months or years, epidemiologic studies have estimated case-fatality rates of ~0.1{\%}, principally from neurologic disease in older patients. There are no licensed vaccines or effective therapies to prevent or treat human CHIKV infections. We have developed a live CHIKV vaccine (CHIKV/IRES) that is highly attenuated yet immunogenic in mouse models, and is incapable of replicating in mosquito cells. In this study we sought to decipher the role of adaptive immunity elicited by CHIKV/IRES in protection against wild-type CHIKV infection. A single dose of vaccine effectively activated T cells with an expansion peak on day 10 post immunization and elicited memory CD4+ and CD8+ T cells that produced IFN-γ, TNF-α and IL-2 upon restimulation with CHIKV/IRES. Adoptive transfer of CHIKV/IRES-immune CD4+ or CD8+ T cells did not confer protection against wtCHIKV-LR challenge. By contrast, passive immunization with anti-CHIKV/IRES immune serum provided protection, and a correlate of a minimum protective neutralizing antibody titer was established. Overall, our findings demonstrate the immunogenic potential of the CHIKV/IRES vaccine and highlight the important role that neutralizing antibodies play in protection against an acute CHIKV infection.",
keywords = "A129 mice, Cellular immunity, Chikungunya (CHIKV), Humoral immunity, Interferon (IFN), Protection",
author = "Haiyan Chu and Das, {Subash C.} and Fuchs, {Jeremy F.} and M. Suresh and Scott Weaver and Stinchcomb, {Dan T.} and Partidos, {Charalambos D.} and Osorio, {Jorge E.}",
year = "2013",
month = "7",
day = "18",
doi = "10.1016/j.vaccine.2013.05.059",
language = "English (US)",
volume = "31",
pages = "3353--3360",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "33",

}

TY - JOUR

T1 - Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model

AU - Chu, Haiyan

AU - Das, Subash C.

AU - Fuchs, Jeremy F.

AU - Suresh, M.

AU - Weaver, Scott

AU - Stinchcomb, Dan T.

AU - Partidos, Charalambos D.

AU - Osorio, Jorge E.

PY - 2013/7/18

Y1 - 2013/7/18

N2 - Chikungunya virus (CHIKV), a mosquito-borne alphavirus, recently re-emerged in Africa and spread to islands in the Indian Ocean, the Indian subcontinent, and to South East Asia. Viremic travelers have also imported CHIKV to the Western hemisphere highlighting the importance of CHIKV in public health. In addition to the great burden of arthralgic disease, which can persist for months or years, epidemiologic studies have estimated case-fatality rates of ~0.1%, principally from neurologic disease in older patients. There are no licensed vaccines or effective therapies to prevent or treat human CHIKV infections. We have developed a live CHIKV vaccine (CHIKV/IRES) that is highly attenuated yet immunogenic in mouse models, and is incapable of replicating in mosquito cells. In this study we sought to decipher the role of adaptive immunity elicited by CHIKV/IRES in protection against wild-type CHIKV infection. A single dose of vaccine effectively activated T cells with an expansion peak on day 10 post immunization and elicited memory CD4+ and CD8+ T cells that produced IFN-γ, TNF-α and IL-2 upon restimulation with CHIKV/IRES. Adoptive transfer of CHIKV/IRES-immune CD4+ or CD8+ T cells did not confer protection against wtCHIKV-LR challenge. By contrast, passive immunization with anti-CHIKV/IRES immune serum provided protection, and a correlate of a minimum protective neutralizing antibody titer was established. Overall, our findings demonstrate the immunogenic potential of the CHIKV/IRES vaccine and highlight the important role that neutralizing antibodies play in protection against an acute CHIKV infection.

AB - Chikungunya virus (CHIKV), a mosquito-borne alphavirus, recently re-emerged in Africa and spread to islands in the Indian Ocean, the Indian subcontinent, and to South East Asia. Viremic travelers have also imported CHIKV to the Western hemisphere highlighting the importance of CHIKV in public health. In addition to the great burden of arthralgic disease, which can persist for months or years, epidemiologic studies have estimated case-fatality rates of ~0.1%, principally from neurologic disease in older patients. There are no licensed vaccines or effective therapies to prevent or treat human CHIKV infections. We have developed a live CHIKV vaccine (CHIKV/IRES) that is highly attenuated yet immunogenic in mouse models, and is incapable of replicating in mosquito cells. In this study we sought to decipher the role of adaptive immunity elicited by CHIKV/IRES in protection against wild-type CHIKV infection. A single dose of vaccine effectively activated T cells with an expansion peak on day 10 post immunization and elicited memory CD4+ and CD8+ T cells that produced IFN-γ, TNF-α and IL-2 upon restimulation with CHIKV/IRES. Adoptive transfer of CHIKV/IRES-immune CD4+ or CD8+ T cells did not confer protection against wtCHIKV-LR challenge. By contrast, passive immunization with anti-CHIKV/IRES immune serum provided protection, and a correlate of a minimum protective neutralizing antibody titer was established. Overall, our findings demonstrate the immunogenic potential of the CHIKV/IRES vaccine and highlight the important role that neutralizing antibodies play in protection against an acute CHIKV infection.

KW - A129 mice

KW - Cellular immunity

KW - Chikungunya (CHIKV)

KW - Humoral immunity

KW - Interferon (IFN)

KW - Protection

UR - http://www.scopus.com/inward/record.url?scp=84879880252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879880252&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.05.059

DO - 10.1016/j.vaccine.2013.05.059

M3 - Article

VL - 31

SP - 3353

EP - 3360

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 33

ER -